CN Patent

CN104169286B — 用于治疗增殖性疾病的大环衍生物

Assigned to SmithKline Beecham Ltd · Expires 2016-06-08 · 10y expired

What this patent protects

本发明涉及式(Φ)的化合物 (其在本文中进一步定义)并涉及其药学上可接受的盐，含有该化合物及盐类的药物组合物以及其用途。本发明的化合物及盐类抑制间变性淋巴瘤酶(ALK)和/或EML4-ALK并可用于治疗或改善异常细胞增殖性病症(例如癌症)。

USPTO Abstract

本发明涉及式(Φ)的化合物 (其在本文中进一步定义)并涉及其药学上可接受的盐，含有该化合物及盐类的药物组合物以及其用途。本发明的化合物及盐类抑制间变性淋巴瘤酶(ALK)和/或EML4-ALK并可用于治疗或改善异常细胞增殖性病症(例如癌症)。

Drugs covered by this patent

Patent Metadata

Patent number
CN104169286B
Jurisdiction
CN
Classification
—
Expires
2016-06-08
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.